UK Firms Lead As EU Biotechs Complete Best Ever 1Q VC Fundraising

04 Apr 2016

• By Mike Ward

Europe's biotech sector has just registered its best ever 1Q fundraising from venture capital sources. While the opportunities for conducting initial public offerings have all but dried up, European biotechs announced VC commitments of more than $600m – almost double the amount raised in the equivalent quarter in 2015 – with UK firms taking three of the top 10 slots.

Top of the pile was Mission Therapeutics, a UK-based a drug discovery and development company focused on selectively targeting deubiquitinating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, which raised £60m

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

01 May 2025

• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

25 Apr 2025

• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Sebela’s Tegoprazan Poised For GERD Market

23 Apr 2025

• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

22 Apr 2025

• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.